[Letter to the Editor] Genetic Control
By Marcy Darnovsky,
The New Yorker
| 12. 14. 2015
Specter highlights exciting developments in the field of gene editing, but he is too quick to dismiss the shadow side. Writing that CRISPR “offers a new outlet for the inchoate fear of tinkering with the fundamentals of life” is an inadequate characterization of the risks involved. The piece describes a nightmare of Jennifer Doudna’s, in which she tutors Hitler about editing genes, but does not reference Eric Lander’s sober warning, in an article on heritable genome manipulation, in the New England Journal of Medicine. Specter does not mention that dozens of countries, including most with developed biotech sectors, have written prohibitions on heritable genetic manipulation into their laws, and into a binding international treaty. In distinguishing the public—and its advocates—from scientists, Specter might lead readers to erroneously believe that researchers are not deeply concerned. Nearly all scientists want a broad public debate about what kind of gene editing should be pursued. This is a potentially society-altering technology, and democratic engagement with its trajectory is crucial and pressing.
Marcy Darnovsky
Executive Director, Center for Genetics and Society
Berkeley, Calif.
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...